Endo International PLC banner
E

Endo International PLC
LSE:0Y5F

Watchlist Manager
Endo International PLC
LSE:0Y5F
Watchlist
Price: 1 038.82 USD 3.04% Market Closed
Market Cap: $233.1B

Endo International PLC
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Endo International PLC
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
E
Endo International PLC
LSE:0Y5F
Operating Income
$259.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Perrigo Company PLC
NYSE:PRGO
Operating Income
$312.8m
CAGR 3-Years
23%
CAGR 5-Years
3%
CAGR 10-Years
-8%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Operating Income
$517.6m
CAGR 3-Years
68%
CAGR 5-Years
0%
CAGR 10-Years
0%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Operating Income
-$5m
CAGR 3-Years
63%
CAGR 5-Years
31%
CAGR 10-Years
19%
G
GH Research PLC
NASDAQ:GHRS
Operating Income
-$60.7m
CAGR 3-Years
-26%
CAGR 5-Years
-167%
CAGR 10-Years
N/A
Cosmo Pharmaceuticals NV
SIX:COPN
Operating Income
-€3.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
5%
No Stocks Found

Endo International PLC
Glance View

Market Cap
233.1B USD
Industry
Pharmaceuticals

Endo International PLC is a specialty pharmaceutical company that operates at the intersection of innovation and necessity within the healthcare industry. Its primary business involves developing, manufacturing, and marketing both branded and generic pharmaceutical products. Endo thrives on a diversified portfolio that spans numerous therapeutic areas, including pain management, urology, orthopedics, and endocrinology. The company strategically positions itself by addressing unmet medical needs, often targeting niche markets where the competition is minimal, thus allowing for premium pricing and robust profit margins. Endo's revenue streams are driven by a blend of proprietary and generic drugs, with a significant portion coming from its well-known brands such as PERCOCET® and SUPPRELIN® LA. Its generics division supplements this by producing cost-effective versions of popular drugs, supporting market accessibility and appealing to cost-sensitive consumers and healthcare providers. By leveraging its research and development capabilities, Endo continues to enhance its product portfolio and explore new market opportunities. The company's growth is rooted in its ability to adapt to the ever-changing regulatory landscape, optimize its operations for efficiency, and forge strategic partnerships that enhance its market reach.

0Y5F Intrinsic Value
Not Available
E

See Also

What is Endo International PLC's Operating Income?
Operating Income
259.8m USD

Based on the financial report for Dec 31, 2022, Endo International PLC's Operating Income amounts to 259.8m USD.

What is Endo International PLC's Operating Income growth rate?
Operating Income CAGR 1Y
-67%

Over the last year, the Operating Income growth was -67%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett